Table 2.
Comparisons among the number of B- and T-cell subsets (expressed as percentage and absolute number) between patients and healthy controls, and between patients before and after 6 and 12 months of treatment with belimumab.
| HC (n = 14) | T0 (n = 14) | T6 (n = 14) | T12 (n = 13) | p HC vs. patients at T0 (n = 14) | PT0 vs. T6 (n = 14) | p T0 vs. T12 (n = 13) | p T6 vs. T12 (n = 13) | |
|---|---|---|---|---|---|---|---|---|
| B Cells | ||||||||
| CD19+ (% lymphocytes) | 8 (6-9) | 8 (3-22) | 5 (2-7) | 3 (1-5) | 0.70 | 0.02 | 0.0022 | 0.02 |
| CD19+ (cell/μl) | 153 (120-229) | 82 (15-361) | 23 (11-57) | 19 (6-55) | 0.050 | 0.0088 | 0.0047 | 0.72 |
| CD19+ SW (% CD19+) | 17 (12-24) | 16 (5-39) | 35 (15-56) | 44 (16-61) | 0.80 | 0.0037 | 0.0046 | 0.15 |
| CD19+ SW (cell/μl) | 28 (19-48) | 11 (5-29) | 6 (2-20) | 4 (2-25) | 0.01 | 0.24 | 0.53 | 0.79 |
| CD19+ UNSW (% CD19+) | 2 (0-8) | 5 (0-13) | 6 (2-20) | 7 (3-12) | 0.20 | 0.27 | 0.86 | 0.19 |
| CD19+ UNSW (cell/μl) | 3 (2-12) | 2 (1-9) | 2 (1-6) | 1 (0-4) | 0.50 | 0.17 | 0.050 | 0.24 |
| CD19+ naïve (% CD19+) | 62 (40-71) | 45 (15-82) | 21 (8-43) | 19 (8-35) | 0.20 | 0.0019 | 0.0019 | 0.15 |
| CD19+ naïve (cell/μl) | 97 (40-155) | 36 (4-235) | 4 (2-13) | 5 (1-10) | 0.20 | 0.0024 | 0.0029 | 0.37 |
| TRANSITIONAL (% CD19+) | 1 (0-3) | 0.6 (0-8) | 0.5 (0-4) | 0.5 (0-6) | 0.60 | 0.38 | 0.63 | 0.28 |
| TRANSITIONAL (cell/μl) | 1 (0-4) | 1 (0-9) | 0 (0-1) | 0.2 (0-1) | 0.80 | 0.03 | 0.03 | 0.33 |
| T cells | ||||||||
| CD4+ (% lymphocytes) | 49 (40-65) | 43 (30-64) | 47 (30-55) | 46 (34-58) | 0.20 | 0.50 | 0.10 | 0.50 |
| CD4+ (cell/μl) | 1131 (716-1370) | 365 (97-1002) | 326 (170-693) | 317 (99-592) | 0.0004 | 0.07 | 0.90 | 0.50 |
| CD4+ RTE (% CD4+) | 18 (9-25) | 20 (14-38) | 17 (3-35) | 10 (3-27) | 0.20 | 0.30 | 0.01 | 0.07 |
| CD4+ RTE (cell/μl) | 240 (70-286) | 95 (31-177) | 68 (6-106) | 30 (18-74) | 0.03 | 0.09 | 0.10 | 0.30 |
| CD8+ (% lymphocytes) | 25 (20-30) | 27 (19-43) | 32 (18-40) | 31 (20-41) | 0.40 | 0.90 | 0.10 | 0.70 |
| CD8+ (cell/μl) | 516 (241-733) | 340 (85-501) | 258 (67-414) | 254 (86-410) | 0.01 | 0.050 | 0.80 | 0.70 |
| CD8+ EM (% CD8+) | 32 (13-45) | 26 (15-37) | 22 (14-37) | 26 (9-51) | 0.30 | 0.60 | 0.60 | 0.10 |
| CD8+ EM (cell/μl) | 133 (14-286) | 61 (24-118) | 53 (10-110) | 54 (16-174) | 0.09 | 0.04 | 0.50 | 0.050 |
Data are expressed as median (10th–90th percentile). HC, Healthy Controls; SW, Switched B-cells; UNSW, Unswitched B-cells; EM, Effector memory T-cells; RTE, Recent Thymic Emigrants T-cells. Mann–Whitney test or Wilcoxon signed-rank test was used for the comparisons, when appropriate. In bold p ≤ 0.050.